Methods and systems for somatic mutations and uses thereof
By performing large-scale parallel nucleic acid sequencing of tumor samples, detecting sequence reads at hybrid SNP positions, and calculating the significance score of somatic mutations, the problem of low detection sensitivity of somatic variants and comparative samples in the prior art is solved. Highly sensitive somatic variant detection and tumor mutation burden assessment are achieved to support cancer treatment choice and prognosis.
Patent Information
- Application Number
- CN202410868756.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-11-01
- Filing Date
- 2019-11-12
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to detect somatic variants with high sensitivity, especially at low frequencies, and conventional sequencing methods require samples of non-cancer germline comparator, with racial bias and errors, and it is impossible to accurately detect and count somatic variants.
By performing large-scale parallel nucleic acid sequencing of tumor samples, mapped to the reference genome, detecting sequence reads at heterozygous SNP positions, calculate somatic mutation significance scores and tumor mutation load, and counting and normalization using Formula I and II , high sensitivity detection and counting of somatic variants is achieved without the need for non-cancer comparator samples.
High sensitivity detection and counting of somatic variants is achieved, reducing racial bias and error, providing accurate assessment of tumor mutation burden, supporting cancer treatment choices and prognosis.
Smart Images

Figure CN118932031A_ABST
Abstract
Description
[0001] This application is a divisional application. The filing date of the original application is November 12, 2019, the application number is 2019800799871 (PCT / US2019 / 061036), and the name of the invention is “Methods and systems for somatic mutation and their uses”. Technical Field
[0002] The present invention relates to methods, compositions, kits and systems for detecting somatic mutations in cancer cells by nucleic acid sequencing. More specifically, the present disclosure provides methods for measuring tumor mutation load, for identifying and treating subjects who benefit from treatment with anticancer agents such as immune checkpoint inhibitors, for treating cancer in subjects, and for monitoring and predicting subjects with cancer. Background Art
[0003] One of the hallmarks of cancer in cells is the presence of somatic variants in the genome. See, for example, Theodor Boveri, J. Cell Sci. (2008) 121: 1-84. Somatic variants can be used as biomarkers for cancer, particularly when the frequency of variants can be accurately detected and recorded. However, it is difficult to quantitatively detect somatic variants.
[0004] The frequency of somatic variants in cancer cells can range from less than 0.1 to hundreds per Mb. Disadvantages of methods for detecting somatic variants include low sensitivity due to the low frequency of variants. Attempts to identify and count somatic variants at low frequencies may not be able to overcome the noise level in high-throughput nucleic acid sequencing methods.
[0005] Furthermore, in nucleic acid sequencing methods that require a reference genome, insufficient representation of various alleles in the reference genome may lead to inaccuracies due to population or ethnic biases.
[0006] A significant disadvantage of some conventional sequencing methods is the need for non-cancer germline comparator samples to distinguish germline variants from variants detected in cancer samples. Non-cancer germline comparator samples can provide a baseline to be subtracted from somatic variants detected in cancer cells. In fact, in many cases, such comparator samples may not even be available.
[0007] What are needed are methods, compositions and systems for detecting somatic variants with high sensitivity.It is also desirable to improve sequencing methods to accurately detect and enumerate somatic variants.
[0008] There is an urgent need for methods for treating cancer and identifying subjects who would benefit from treatment. What is needed are methods and systems that do not require non-cancer comparator samples and tumor or tissue samples from subjects with cancer.
[0009] There has long been a need to achieve these goals through methods involving direct detection of variants to reduce errors. Summary of the invention
[0010] The present invention provides methods, compositions, kits and systems for detecting somatic mutations in cancer cells, for identifying and treating subjects who benefit from treatment with anti-cancer agents such as immune checkpoint inhibitors, for measuring tumor mutation load, for treating cancer in a subject, and for monitoring and prognosticating subjects with cancer.
[0011] Measurement of somatic mutations can inform cancer treatment, diagnosis, and prognosis.
[0012] In some aspects, the invention provides methods for selecting and identifying subjects who benefit from treatment (such as using anticancer agents to treat cancer).For these subjects, a treatment modality can be selected to treat cancer.
[0013] In another aspect, the invention provides a method for measuring and scoring the frequency of tumor mutations in cancer cells. The score can be used to calculate the tumor mutation load of a sample from a subject. The tumor mutation load can serve as a biomarker for a disease, such as cancer.
[0014] Somatic variants can be associated with a subject's response to treatment with certain drugs. For example, a high tumor mutation load value can be associated with a favorable response in a subject with cancer to administration of an immune checkpoint inhibitor drug.
[0015] Embodiments of the present invention include:
[0016] A method for detecting a somatic variant, the method comprising:
[0017] (a) sequencing cells of a sample;
[0018] (b) identifying a set of heterozygous SNP positions, wherein each SNP has alleles B and A;
[0019] (c) detecting variants at a SNP position of two germline allele pairs and positions near the SNP position, wherein the two germline allele pairs are (i) allele B and a first variant allele and (ii) allele A and a second variant allele, the second variant allele may be the same as or different from the first variant allele; and
[0020] (d) detecting the third allele pairing, wherein the third allele pairing is (iii) allele B and the third variant allele, and the third variant allele is different from the first variant allele. The allele pairing can be detected in a continuous nucleic acid sequence containing one of the SNP positions, so that the variant position is located within a detection length of the SNP position. The read length of the continuous nucleic acid sequence can be about 100 to 5000 bases. The detection length can be 200 to 1000 continuous base positions on each flank of the SNP position. The method does not utilize a separate germline comparison sample. The sample can be a cancer tissue sample, a tumor cell sample or a tumor sample. The amount of non-tumor cells in the sample can be minimized. The sample can contain non-tumor cells. Allele pairing can be detected by massive parallel sequencing, by hybridization or by amplification. The group of heterozygous SNP positions can be at least 500 SNP positions or at least 1000 SNP positions or at least 5000 SNP positions. The method can detect somatic variants at a minimum level of 0.1 per Mb or 0.3 per Mb or 0.7 per Mb. Detection can be obtained using a targeted SNP panel. The detection can be obtained by using fragmented sequencing of a human reference genome.
[0021] A method for detecting a somatic variant, the method comprising:
[0022] (a) sequencing cells from a tumor sample;
[0023] (b) obtaining sequence reads from the sample using a massively parallel nucleic acid sequencing method, wherein the sequence reads have a read length;
[0024] (c) mapping the sequence reads to a reference genome;
[0025] (d) assembling a somatic variant count matrix of sequence reads mapped to heterozygous SNP positions of the reference genome, wherein the count matrix has a first element and a second element, the first element and the second element count allele pairings of SNP alleles B and A with variant alleles, respectively, and wherein the count matrix has a third element, the third element counts read sequences from SNP allele B paired with a different variant allele in the first element; and
[0026] (e) calculating the somatic mutation significance score (S) of the third element. The method does not utilize a separate germline comparator sample. The sample can be a cancer tissue sample, a tumor cell sample, or a tumor sample. The method can detect somatic variants at a minimum level of 0.1 per Mb or 0.3 per Mb or 0.7 per Mb. Sequence reads can be obtained with a targeted SNP panel. The read length can be 100 to 5000 or 200 to 1000 continuous base positions. For the covered portion of the reference genome, the average read depth can be at least 50x or 100x. The reference genome can be a human genome. Sequence reads can be error filtered and position filtered.
[0027] The somatic mutation significance score (S) is given by Formula I:
[0028] S=(C(Z,P) 2 / (C(Z,P)+C(X,P))+(C(Z,P)-E) 2 / E) / 2*10 formula I
[0029] Where C(Z,P) is the third element count, C(X,P) is the first element count, and E is the error rate calculated for all SNP regions from the average of all but the top three counts in the matrix.
[0030] A method for identifying a subject with cancer who would benefit from treatment, the method comprising:
[0031] (a) sequencing cells from a tumor sample from the subject;
[0032] (b) identifying a set of heterozygous SNP positions, wherein each SNP has alleles B and A;
[0033] (c) detecting variants at a SNP position of two germline allele pairs and positions near the SNP position, wherein the two germline allele pairs are (i) allele B and a first variant allele and (ii) allele A and a second variant allele, the second variant allele may be the same as or different from the first variant allele; and
[0034] (d) detecting a third allele pair, the third allele pair being (iii) allele B and a third variant allele, the third variant allele being different from the first variant allele, wherein the third allele pair is derived from a somatic variant;
[0035] (f) calculating a value for tumor mutation burden from said somatic variants detected from said allele pairing; and
[0036] (g) identifying the subject suffering from cancer as benefiting from treatment if the tumor mutation load is greater than a reference level.
[0037] A method for identifying a subject with cancer who would benefit from treatment, the method comprising:
[0038] (a) sequencing cells from a tumor sample from the subject;
[0039] (b) obtaining sequence reads from the sample using a massively parallel nucleic acid sequencing method, wherein the sequence reads have a read length;
[0040] (c) mapping the sequence reads to a reference genome;
[0041] (d) assembling a somatic variant count matrix of sequence reads mapped to heterozygous SNP positions of the reference genome, wherein the count matrix has a first element and a second element, the first element and the second element count allele pairings of SNP alleles B and A with variant alleles, respectively, and wherein the count matrix has a third element, the third element counts read sequences from SNP allele B paired with a different variant allele in the first element;
[0042] (e) calculating the tumor mutation load value of the sample by the following steps:
[0043] (i) calculating a somatic mutation significance score (S) of the third element; and
[0044] (ii) calculating said value of said tumor mutation burden from the number of somatic variants with a somatic mutation significance score above a threshold, said number being normalized by the total number of positions in the heterozygous SNP region; and
[0045] (f) If the tumor mutation load is greater than the somatic mutation reference level, the subject with cancer is identified as benefiting from treatment. The number of heterozygous SNPs in the reference genome can be about 100 up to the total number of heterozygous SNPs in the reference genome. The somatic mutation reference level can be a level at which the subject will benefit from the treatment. The somatic mutation reference level can be the average tumor mutation load of the reference genome. The somatic mutation reference level can be the average tumor mutation load of a reference population suffering from the same type of cancer as the subject. The somatic mutation reference level can be the average tumor mutation load of a reference population that does not suffer from cancer. The somatic mutation reference level can be the average tumor mutation load of a reference population that does not benefit from the treatment. The somatic mutation reference level can be obtained with different samples from the subject. The tumor mutation load threshold can be 15 or 20 or 30 or 40, and the tumor mutation load is given by Formula II:
[0046] TMB=N(S>threshold) / (N(HomHet)+N(HetHet))*1000000 Formula II
[0047] where N is the number of somatic variants with somatic mutation significance scores above the threshold, normalized by the total number of positions in the heterozygous SNP region (N(HomHet)+N(HetHet)).
[0048] A method for treating cancer in a subject in need thereof, the method comprising:
[0049] (a) sequencing cells from a tumor sample from the subject;
[0050] (b) identifying a set of heterozygous SNP positions, wherein each SNP has alleles B and A;
[0051] (c) detecting variants at a SNP position of two germline allele pairs and positions near the SNP position, wherein the two germline allele pairs are (i) allele B and a first variant allele and (ii) allele A and a second variant allele, the second variant allele may be the same as or different from the first variant allele; and
[0052] (d) detecting a third allele pair, the third allele pair being (iii) allele B and a third variant allele, the third variant allele being different from the first variant allele, wherein the third allele pair is derived from a somatic variant;
[0053] (e) calculating a value of tumor mutation load from said detected somatic variants;
[0054] (f) identifying the subject having cancer as benefiting from treatment if the tumor mutation load is greater than a reference level; and
[0055] (g) administering cancer therapy.
[0056] A method for treating cancer in a subject in need thereof, the method comprising:
[0057] (a) sequencing cells from a tumor sample from the subject;
[0058] (b) obtaining sequence reads from the sample using a massively parallel nucleic acid sequencing method, wherein the sequence reads have a read length;
[0059] (c) mapping the sequence reads to a reference genome;
[0060] (d) assembling a somatic variant count matrix of sequence reads mapped to heterozygous SNP positions of the reference genome, wherein the count matrix has a first element and a second element, the first element and the second element count allele pairings of SNP alleles B and A with variant alleles, respectively, and wherein the count matrix has a third element, the third element counts read sequences from SNP allele B paired with a different variant allele in the first element;
[0061] (e) calculating the tumor mutation load value of the sample by the following steps:
[0062] (i) calculating a somatic mutation significance score (S) of the third element for each somatic variant; and
[0063] (ii) calculating said value of said tumor mutation burden from the number of somatic variants with a somatic mutation significance score above a threshold, said number being normalized by the total number of positions in the heterozygous SNP region;
[0064] (f) identifying that the subject having cancer will benefit from treatment if the tumor mutation load is greater than a somatic mutation reference level; and
[0065] (g) administering cancer therapy. The cancer therapy may include administering an immune checkpoint inhibitor drug.
[0066] A method for treating cancer in a subject in need thereof, the method comprising:
[0067] (a) sequencing cells from a tumor sample from the subject;
[0068] (b) obtaining sequence reads from the sample using a massively parallel nucleic acid sequencing method, wherein the sequence reads have a read length;
[0069] (c) mapping the sequence reads to a reference genome;
[0070] (d) assembling a somatic variant count matrix of sequence reads mapped to heterozygous SNP positions of the reference genome, wherein the count matrix has a first element and a second element, the first element and the second element count allele pairings of SNP alleles B and A with variant alleles, respectively, and wherein the count matrix has a third element, the third element counts read sequences from SNP allele B paired with a different variant allele in the first element;
[0071] (e) calculating the tumor mutation load value of the sample by the following steps:
[0072] (i) calculating a somatic mutation significance score (S) of the third element for each somatic variant; and
[0073] (ii) calculating said value of said tumor mutation burden from the number of somatic variants with a somatic mutation significance score above a threshold, said number being normalized by the total number of positions in the heterozygous SNP region;
[0074] (f) identifying that the subject having cancer will benefit from treatment if the tumor mutation load is greater than a somatic mutation reference level;
[0075] (g) monitoring the subject over a period of time for signs and symptoms of cancer; and
[0076] (h) administering cancer therapy. The therapy may be administration of an immune checkpoint inhibitor.
[0077] A method for monitoring the response of a subject having cancer to treatment, the method comprising:
[0078] (a) sequencing cells from a tumor sample from the subject;
[0079] (b) identifying a set of heterozygous SNP positions, wherein each SNP has alleles B and A;
[0080] (c) detecting variants at a SNP position of two germline allele pairs and positions near the SNP position, wherein the two germline allele pairs are (i) allele B and a first variant allele and (ii) allele A and a second variant allele, the second variant allele may be the same as or different from the first variant allele; and
[0081] (d) detecting a third allele pair, the third allele pair being (iii) allele B and a third variant allele, the third variant allele being different from the first variant allele, wherein the third allele pair is derived from a somatic variant;
[0082] (e) calculating a value for tumor mutation burden from said detected somatic variants.
[0083] A method for monitoring the response of a subject having cancer to treatment, the method comprising:
[0084] (a) sequencing cells from a tumor sample from the subject;
[0085] (b) obtaining sequence reads from the sample using a massively parallel nucleic acid sequencing method, wherein the sequence reads have a read length;
[0086] (c) mapping the sequence reads to a reference genome;
[0087] (d) assembling a somatic variant count matrix of sequence reads mapped to heterozygous SNP positions of the reference genome, wherein the count matrix has a first element and a second element, the first element and the second element count allele pairings of SNP alleles B and A with variant alleles, respectively, and wherein the count matrix has a third element, the third element counts read sequences from SNP allele B paired with a different variant allele in the first element;
[0088] (e) calculating the tumor mutation load value of the sample by the following steps:
[0089] (i) calculating a somatic mutation significance score (S) of the third element for each somatic variant; and
[0090] (ii) calculating said value of said tumor mutation burden from the number of somatic variants with a somatic mutation significance score above a threshold, said number being normalized by the total number of positions in the heterozygous SNP region.
[0091] A method for prognosing a subject suffering from cancer, the method comprising:
[0092] (a) sequencing cells from a tumor sample from the subject;
[0093] (b) identifying a set of heterozygous SNP positions, wherein each SNP has alleles B and A;
[0094] (c) detecting variants at a SNP position of two germline allele pairs and positions near the SNP position, wherein the two germline allele pairs are (i) allele B and a first variant allele and (ii) allele A and a second variant allele, the second variant allele may be the same as or different from the first variant allele; and
[0095] (d) detecting a third allele pair, the third allele pair being (iii) allele B and a third variant allele, the third variant allele being different from the first variant allele, wherein the third allele pair is derived from a somatic variant;
[0096] (e) calculating a value for tumor mutational burden from said detected somatic variants; and
[0097] (f) if the tumor mutation burden is greater than the TMB reference level, prognosing the subject as having a poor prognosis.
[0098] A method for prognosing a subject suffering from cancer, the method comprising:
[0099] (a) sequencing cells from a tumor sample from the subject;
[0100] (b) obtaining sequence reads from the sample using a massively parallel nucleic acid sequencing method, wherein the sequence reads have a read length;
[0101] (c) mapping the sequence reads to a reference genome;
[0102] (d) assembling a somatic variant count matrix of sequence reads mapped to heterozygous SNP positions of the reference genome, wherein the count matrix has a first element and a second element, the first element and the second element count allele pairings of SNP alleles B and A with variant alleles, respectively, and wherein the count matrix has a third element, the third element counts read sequences from SNP allele B paired with a different variant allele in the first element;
[0103] (e) calculating the tumor mutation load value of the sample by the following steps:
[0104] (i) calculating a somatic mutation significance score (S) of the third element for each somatic variant; and
[0105] (ii) calculating said value of said tumor mutation burden from the number of somatic variants with a somatic mutation significance score above a threshold, said number being normalized by the total number of positions in the heterozygous SNP region;
[0106] (f) if the tumor mutation burden is greater than the TMB reference level, prognosing the subject as having a poor prognosis; and
[0107] (g) administering cancer therapy.
[0108] A kit for identifying a subject with cancer who would benefit from treatment, the kit comprising:
[0109] (a) reagents for obtaining sequence reads from a sample from the subject, wherein the sequence reads can be used to obtain a value for tumor mutation load of the sample; and
[0110] (b) instructions for using said reagents for obtaining said sequence reads and using said value of tumor mutation load for identifying said subject.
[0111] A system for detecting somatic variants, the system comprising:
[0112] a device for receiving, enriching and amplifying nucleic acids from a sample, wherein the sample contains cancer cells and non-cancerous cells;
[0113] means for synthesizing a library from said nucleic acid;
[0114] A device for contacting the library with a sequencing chip;
[0115] means for detecting sequences in said library and transmitting sequence data to a processor;
[0116] One or more processors, the one or more processors configured to perform the following steps:
[0117] (a) providing a sample containing cancer cells and non-cancerous cells;
[0118] (b) obtaining sequence reads from the sample using a massively parallel nucleic acid sequencing method, wherein the sequence reads have a read length;
[0119] (c) mapping the sequence reads to a reference genome;
[0120] (d) assembling a somatic variant count matrix of sequence reads mapped to heterozygous SNP positions of the reference genome, wherein the count matrix has a first element and a second element, the first element and the second element count allele pairings of SNP alleles B and A with variant alleles, respectively, and wherein the count matrix has a third element, the third element counts read sequences from SNP allele B paired with a different variant allele in the first element;
[0121] (e) calculating the tumor mutation load value of the sample by the following steps:
[0122] (i) calculating a somatic mutation significance score (S) of the third element for each somatic variant; and
[0123] (ii) calculating said value of said tumor mutation burden from the number of somatic variants with a somatic mutation significance score above a threshold, said number being normalized by the total number of positions in the heterozygous SNP region; and
[0124] A display is used to display, graph and report sequence information.
[0125] A non-transitory machine-readable storage medium having stored therein instructions for execution by a processor, the instructions causing the processor to perform the steps of a method for detecting a somatic variant, the method comprising:
[0126] (a) providing a sample containing cancer cells and non-cancerous cells;
[0127] (b) obtaining sequence reads from the sample using a massively parallel nucleic acid sequencing method, wherein the sequence reads have a read length;
[0128] (c) mapping the sequence reads to a reference genome;
[0129] (d) assembling a somatic variant count matrix of sequence reads mapped to heterozygous SNP positions of the reference genome, wherein the count matrix has a first element and a second element, the first element and the second element count allele pairings of SNP alleles B and A with variant alleles, respectively, and wherein the count matrix has a third element, the third element counts read sequences from SNP allele B paired with a different variant allele in the first element;
[0130] (e) calculating the tumor mutation load value of the sample by the following steps:
[0131] (i) calculating a somatic mutation significance score (S) of the third element for each somatic variant; and
[0132] (ii) calculating said value of said tumor mutation burden from the number of somatic variants with a somatic mutation significance score above a threshold, said number being normalized by the total number of positions in the heterozygous SNP region; and
[0133] (f) displaying, graphing and reporting sequence information from the sample. BRIEF DESCRIPTION OF THE DRAWINGS
[0134] Figure 1: Schematic representation of methods and procedures for detecting and assessing tumor mutation burden by nucleic acid sequencing.
[0135] Figure 2 : Illustration of germline alleles and germline variants. (Top) Germline alleles of heterozygous variant V / W, which are located near heterozygous SNP B / A. Each SNP allele is associated with only one variant allele, and for reads covering both SNP and VAR positions, only two unique sequence reads BV and AW are expected. (Bottom) Germline alleles of homozygous variant W / W, which are located near heterozygous SNP B / A. Each SNP allele is associated with only one variant allele, and for reads covering both SNP and VAR positions, only two unique sequence reads BW and AW are expected.
[0136] Figure 3 : Illustration of somatic alleles and somatic variants. (Top) Alleles of heterozygous variant V / W are observed, which are located near heterozygous SNP B / A. For reads covering both SNP and VAR positions, it is expected that two normal alleles pair BV and AW have two unique sequence reads. However, SNP allele B is related to two variant alleles BV and BW. Therefore, BW represents a new mutation. The matrix of these reads shows the large (L) counts of BV and AW, and the (s) counts of BW that may be smaller. (Bottom) Alleles of homozygous variant W / W are observed, which are located near heterozygous SNP B / A. For reads covering both SNP and VAR positions, it is expected that two normal alleles pair BW and AW have two unique sequence reads. However, SNP allele B is related to two variant alleles BV and BW. Therefore, BV represents a new mutation. The matrix of these reads shows the large (L) counts of BW and AW, and the (s) counts of BV that may be smaller.
[0137] Figure 4 :Example embodiment of a method for detecting and assessing tumor mutation load by nucleic acid sequencing. For homozygous somatic variants located near heterozygous SNPs (Hom / Het), sequence read stacks are mapped to a reference genome (WT) as shown. A count matrix showing detection of allele pairings GA (count 55), AA (count 32), and AG (count 23) is assembled. The appearance of the third largest count AG (count 23) originates from somatic mutations in some cancer cells.
[0138] Figure 5: Example embodiment of a method for detecting and assessing tumor mutation load by nucleic acid sequencing. For heterozygous somatic variants located near heterozygous SNPs (Het / Het), a count matrix showing the detection of alleles CG (count 39), GT (count 34), and GG (count 7) was assembled. The appearance of the third largest count GG (count 7) originates from somatic mutations in some cancer cells.
[0139] Figure 6 : A graphic representation of sequencing data from a colon cancer sample. Each curve represents the number of variant positions (Y-axis) by the allele ratio % (X-axis). One sample shows a large peak representing a high TMB sample. The high peak on the left side at very low allele ratio values (less than 10%) reflects the neglected sequencing errors. In order to count TMB values, for scores greater than 30 (Y-axis), TMB values can be calculated as the area under the curve for allele ratios in the range of about 15% to about 65%.
[0140] Figure 7 : A graph of data from the SNP-based method of the present invention for detecting and assessing tumor mutation load in colon cancer and breast cancer samples by nucleic acid sequencing, compared to conventional methods involving subtracting data or germline filtering from germline comparator samples. Using the direct SNP analysis method of the present invention (solid circles) with only tumor samples and no second germline comparator sample, an assessment of tumor mutation load that is surprisingly superior to conventional methods is obtained. The sensitivity of the SNP-based method of the present invention (solid circles) is surprisingly increased compared to conventional methods. More specifically, the SNP-based method of the present invention (solid circles) is surprisingly more accurate than a method for nucleic acid sequencing that uses a database of known germline variants and filters common variants to attempt to remove germline background (open circles) to assess tumor mutation load. DETAILED DESCRIPTION
[0141] The present invention provides methods, compositions, kits and systems for detecting somatic mutations in cancer cells. The measurement results of somatic mutations can provide methods for treating, diagnosing and prognosing cancer.
[0142] In some aspects, the invention provides methods for selecting and identifying subjects who benefit from treatment (such as using anticancer agents to treat cancer).For these subjects, a treatment modality can be selected to treat cancer.
[0143] In another aspect, the invention provides a method for measuring and scoring the frequency of tumor mutations in cancer cells. The score can be used to calculate the tumor mutation load of a sample from a subject. The tumor mutation load can serve as a biomarker for a disease, such as cancer.
[0144] Somatic variants can be associated with a subject's response to treatment with certain drugs. For example, a high tumor mutation load value can be associated with a favorable response in a subject with cancer to administration of an immune checkpoint inhibitor drug.
[0145] As used herein, a quantity related to the frequency of somatic variants can be defined as "tumor mutation burden" (TMB). TMB can be calculated as the count of somatic variants in a cancer sample normalized to the total number of genomic positions determined in determining the count of somatic variants. TMB can be expressed as the number of mutations per megabase of DNA.
[0146] TMB can also be measured from RNA and expressed as the number of mutations per megabase of RNA.
[0147] A measure of TMB may be obtained as a measure of somatic variants in a set of genomic positions. The set of genomic positions may be a set of SNP regions of the genome.
[0148] In some embodiments, sequencing data or sequencing reads can be used to identify a set of heterozygous SNP positions.
[0149] In some embodiments, known human SNP positions can be used to identify a set of heterozygous SNP positions.
[0150] The measurement of TMB of the present invention can be a substitute for the somatic mutation load of the genome. The measurement of TMB of the present invention can provide a numerical level that directly reflects the number of somatic mutations of the genome. The measurement of TMB of the present invention can provide a numerical level that can be an effective estimate of the total mutation load of the genome. The measurement of TMB of the present invention can be different from the amount labeled as "TMB" in other documents.
[0151] In some aspects, the invention provides methods and systems for detecting somatic mutations and determining mutation levels. The mutation load can be obtained from a unique algorithm covering the detection of somatic mutations in a genome, wherein the somatic mutations are each located near a SNP position in an array of SNP positions in the genome.
[0152] In certain aspects, the measure of TMB of the present invention can be obtained from a unique algorithm that encompasses the detection of somatic mutations in a portion of the genome, wherein each somatic mutation is located near a SNP position in an array of SNP positions in the genome.
[0153] In further aspects, the measure of TMB of the invention can provide a numerical level that directly reflects the number of somatic mutations in the genome, where the mutations can affect the function of a location in the genome.
[0154] In further aspects, the methods of the invention for measuring TMB can utilize data obtained by any sequencing technology that provides multiple independent reads of a locus of interest. In various embodiments, a Sanger sequence method can be utilized.
[0155] In further aspects, the methods of the invention for measuring TMB can be utilized with any SNP panel, whole exome / genome sequencing, and genome in which SNPs can be sequenced.
[0156] In some embodiments, HRD (Myriad Genetics, Inc.) sequencing can be used, which is a hybrid capture-based gene panel that also samples SNPs from the entire genome. The HRD assay can utilize SNPs to reconstruct a tumor-CN / LOH profile from which an HRD score can be derived. The HRD assay can be used to sequence a large number of SNP loci.
[0157] In certain embodiments, any sequencing data with a sufficient number of SNPs (including flanking regions on both sides) can be used.
[0158] In further aspects, any sequence-based NGS assay can be used in the methods of the invention for measuring TMB.
[0159] In other aspects, embodiments of the present invention provide methods for treating a subject with cancer. The subject with cancer can be selected and identified by evaluating the tumor mutation load in a sample from the subject. The subject can be treated with an anticancer agent (such as an effective amount of an immune checkpoint inhibitor).
[0160] Aspects of the invention include methods, compositions, and systems for detecting somatic variants in a sample with advantageously superior sensitivity, including the measure of TMB of the invention.
[0161] The present invention may further provide an improved method for sequencing nucleic acids of a sample.The improved sequencing method of the present invention may be used to accurately detect and enumerate somatic variants.
[0162] The embodiments described in the present disclosure include methods for treating cancer and identifying subjects who benefit from treatment. The unique methods of the present invention can be performed with a single sample from a subject without the need for a non-cancer comparator sample. The methods of the present disclosure provide a direct measure of somatic variants, which can be used to determine the value of somatic variant scores and tumor mutation load. Direct measurements of somatic mutations in samples from subjects, such as tumors or tissue samples from subjects with cancer, and assessments of tumor mutation load can provide accurate biomarkers for the disease.
[0163] Additional aspects of the invention include methods for directly detecting somatic variants that can reduce errors due to racial bias. The methods disclosed herein can detect somatic variants from a single test sample by counting sequence reads that can be attributed only to cancer cells. In these methods, tumor mutation loads that are relevant to the individual and less affected by population or racial bias can be determined.
[0164] Tumor mutation load determined by the methods of the invention may be particularly predictive in certain cancers. Tumor mutation load may be used to detect and diagnose cancer, as well as to determine prognosis.
[0165] Examples of cancer include prostate cancer, melanoma, bladder cancer, breast cancer, blood cancer, mesothelioma, lung cancer, and solid tumors.
[0166] In some embodiments, the invention provides methods for assessing tumor mutational burden, where an abnormal state may indicate a poor prognosis.
[0167] In further embodiments, methods for assessing tumor mutational burden can be combined with one or more clinical parameters to diagnose and / or prognose cancer.
[0168] Examples of clinical parameters include, for example, clinical nomograms.
[0169] In certain embodiments, high levels of tumor mutational load can indicate the presence of cancer.
[0170] In further embodiments, a high level of tumor mutation load may indicate an increased risk of cancer recurrence or progression in a subject for whom the clinical nomogram score indicates a relatively low risk of recurrence or progression.
[0171] For example, a high level of tumor mutation load can show an increased risk of cancer recurrence or progression independent of tumor grade or stage or independent of the nomogram score. Thus, a high level of tumor mutation load can detect an increased risk that is not detected using clinical parameters alone.
[0172] In some aspects, the present disclosure provides in vitro diagnostic methods comprising determining at least one clinical parameter of a cancer patient and determining the tumor mutation load in a sample obtained from the patient.
[0173] In some embodiments, an abnormal state of tumor mutational burden may indicate an increased likelihood of cancer recurrence or progression.
[0174] In certain embodiments, the combination of one or more clinical parameters with an assessment of tumor mutation load can improve predictive power regarding cancer. In some embodiments, more than one clinical parameter can be assessed and combined with an assessment of tumor mutation load.
[0175] In additional aspects, the invention encompasses an in vitro diagnostic method comprising determining at least one clinical parameter or nomogram score for a patient and assessing the patient's tumor mutation burden.
[0176] Aspects of the invention include methods of classifying cancer by assessing tumor mutation burden in a tissue or cell sample, more specifically a tumor sample, from a subject.
[0177] Tumor samples of the present disclosure may contain a mixture of cancer and non-cancer normal cells. Tumor samples of the present disclosure may be obtained so as to minimize the non-cancer or non-tumor content in the sample. For example, the non-tumor content in the sample may be minimized by removing only tumor tissue in a biopsy or by removing only lesions with no or minimal normal tissue margins.
[0178] In certain embodiments, it is preferred to minimize the non-tumor content in the sample so that the measured somatic mutations can be related to the amount of tumor mutation load. The amount of tumor mutation load can be used to characterize the level of de novo mutations or somatic mutations in a tumor.
[0179] In other embodiments, the measured somatic mutations can be related to the amount of tumor mutation load even when the sample contains some non-tumor content. The amount of tumor mutation load can be used to characterize the level of de novo mutations or somatic mutations in a tumor sample in order to analyze the clinical status of a subject.
[0180] Embodiments of the present invention can advantageously utilize samples containing cancer and non-cancer cells in methods for detecting somatic mutations without germline subtraction. The methods of the present invention for detecting somatic mutations without germline subtraction can count the number of mutations that are present only in tumors, even in samples containing a mixture of cancer and non-cancer normal cells. The methods of the present invention for detecting somatic mutations without germline subtraction can identify which mutations are present in normal cells and which mutations are present in tumor cells, and only count mutations that are present in tumors.
[0181] In some embodiments, tumor samples of the present disclosure may be obtained so as to minimize non-cancerous content in the sample, thereby allowing somatic mutations to be detected with increased accuracy and / or precision.
[0182] In certain embodiments, the methods of the present invention can advantageously detect somatic mutations in cancer cells without the need for germline subtraction, even in samples containing both cancer and non-cancer cells.
[0183] A reference value for tumor mutation burden can represent the average TMB level of multiple training patients (e.g., cancer patients) with similar outcomes, for which clinical data and follow-up data are available and sufficient to define and classify patients according to disease outcome (e.g., recurrence or prognosis).
[0184] The reference value of TMB can be the TMB level of a population of subjects with cancer who have been treated with an anticancer agent. In some embodiments, the population can include a group of subjects who have been treated with a specific anticancer agent and another group of subjects who have been treated with a different anticancer agent.
[0185] The reference value of TMB may be the TMB level of a population of subjects with cancer who do not respond to treatment with an anticancer agent.
[0186] In some embodiments, TMB values can be distinguished between subjects with different responsiveness to treatment with anticancer agents. In certain embodiments, TMB values can distinguish subjects with increased overall survival or progression-free survival after treatment with anticancer agents from subjects with unincreased survival. In further embodiments, TMB values can identify subjects of a population that benefits from therapeutic treatment or responds to therapeutic treatment.
[0187] A "good prognostic value" can be generated from multiple training cancer patients characterized as having a "good outcome," e.g., patients whose cancer has not recurred within a period of time (e.g., five or ten years or more after initial treatment) or patients whose cancer has not progressed within five or ten years or more after initial diagnosis.
[0188] A "poor prognostic value" can be generated from a plurality of training cancer patients defined as having a "poor outcome," such as patients having cancer recurrence within five or ten years or more after initial treatment or patients having cancer progression within five or ten years or more after initial diagnosis.
[0189] Thus, a good prognostic value may represent the average level of TMB for patients with a "good outcome," whereas a poor prognostic value may represent the average level of TMB for patients with a "poor outcome."
[0190] In some embodiments, when the value of TMB is increased, the subject may have a poor prognosis.
[0191] In certain embodiments, the value of TMB may increase beyond a normal or threshold amount.
[0192] In various embodiments, the value of TMB may be closer to a poor prognosis value than a good prognosis value, which may indicate a poor prognosis for the subject.
[0193] In other embodiments, the value of TMB may be closer to a good prognosis value than a poor prognosis value, which may indicate a good prognosis for the subject.
[0194] In further embodiments, the value of TMB can be determined by assigning patients to risk groups, and a threshold can be set for the TMB mean value.
[0195] The threshold can be selected based on a receiver operating characteristic (ROC) curve, which plots sensitivity versus {1 minus specificity}.
[0196] In some embodiments, the TMB reference level can be about 1 to about 30, or about 2 to about 30, or about 3 to about 30, or about 4 to about 30, or about 5 to about 30, or about 6 to about 30, or about 7 to about 30, or about 8 to about 30, or about 9 to about 30, or about 10 to about 30, or about 10 to about 20 mutations per Mb.
[0197] In some embodiments, the TMB reference level can be about 5 to about 300 or about 10 to about 300 or about 30 to about 300 or about 50 to about 300 mutations per Mb.
[0198] In some embodiments, the TMB reference level can be about 1 or about 2 or about 3 or about 4 or about 5 or about 6 or about 7 or about 8 or about 9 or about 10 or about 20 mutations per Mb.
[0199] In some embodiments, the TMB reference value may be about 30 or about 50 mutations per Mb.
[0200] In general, cancer can be classified by determining one or more clinically relevant features of the cancer and / or determining a specific prognosis for a patient with the cancer. Thus, "classifying a cancer" can include: (i) assessing metastatic potential, potential for metastasis to a specific organ, risk of recurrence, and / or tumor progression; (ii) assessing tumor stage; (iii) determining patient prognosis in the absence of cancer treatment; (iv) determining a patient's prognosis for response to treatment (e.g., chemotherapy, radiotherapy, surgical resection of the tumor, etc.) (e.g., tumor shrinkage or progression-free survival); (v) diagnosing a patient's actual response to current and / or past treatments; (vi) determining a patient's preferred course of treatment; (vii) prognosis of a patient's recurrence after treatment (general treatment or some specific treatment); (viii) prognosis of a patient's life expectancy (e.g., prognosis of overall survival).
[0201] "Negative classification" refers to an unfavorable clinical feature of cancer (e.g., a poor prognosis). Examples include (i) increased metastatic potential, potential for metastasis to a specific organ, and / or risk of recurrence; (ii) advanced tumor stage; (iii) poor patient prognosis in the absence of cancer treatment; (iv) poor prognosis of a patient's response to a specific treatment (e.g., chemotherapy, radiotherapy, surgical resection of a tumor, etc.) (e.g., tumor shrinkage or progression-free survival); (v) poor prognosis of a patient's recurrence after treatment (general treatment or some specific treatment); (vi) poor prognosis of a patient's life expectancy (e.g., prognosis of overall survival).
[0202] In some embodiments, recurrence-associated clinical parameters (or high nomogram scores) and increased TMB may indicate a negative classification of the cancer (eg, increased likelihood of recurrence or progression).
[0203] Typically, the value of TMB increases may be accompanied by rapid proliferation of cancer cells, which may indicate a more aggressive cancer. The likelihood of a subject with an elevated TMB value recurring after treatment may increase. The subject with an elevated TMB value may have an increased likelihood of cancer progression or a more rapid progression, wherein rapidly proliferating cells may cause rapid tumor growth, increased toxicity and / or metastasis. The subject with an elevated TMB value may need a relatively more aggressive treatment.
[0204] In some embodiments, the invention provides methods for classifying cancer by assessing tumor mutational burden, wherein an abnormal state indicates an increased likelihood of recurrence or progression.
[0205] In further embodiments, the present invention provides methods for determining the prognosis of cancer in a subject by assessing tumor mutation burden, wherein an elevated TMB may indicate an increased likelihood of cancer recurrence or progression.
[0206] In other embodiments, the assessment can be performed before cancer surgery, such as using a biopsy sample. In other embodiments, the assessment can be performed after cancer surgery, such as using a resected cancer sample.
[0207] In certain embodiments, a sample of one or more cells may be obtained from a cancer patient before, during, or after treatment.
[0208] Examples of cancer treatments include surgical removal of the affected organ, radiation therapy, hormone therapy (eg, using GnRH antagonists, GnRH agonists, anti-androgens), chemotherapy, and high-intensity focused ultrasound.
[0209] Active surveillance of subjects with cancer involves observation and regular monitoring without invasive treatment. Active treatment may be started during or after surveillance if symptoms develop or if there are signs that cancer growth is ongoing or accelerating.
[0210] Active surveillance may involve an increased risk of cancer metastasis. Surveillance may last for one or more months or a year or many years or longer.
[0211] The present invention can provide a method for treating a cancer patient or providing guidance for selecting a treatment of a patient. In the method, the assessment of TMB and one or more recurrence-related clinical parameters can be determined. If the sample from the patient has an elevated TMB and the patient has one or more recurrence-related clinical parameters, active treatment can be suggested, started or continued. If the patient has neither elevated TMB nor recurrence-related clinical parameters, active monitoring can be suggested or started or continued. In certain embodiments, TMB or TMB and one or more clinical parameters can indicate active treatment or suggest specific active treatment or suggest active treatment.
[0212] Often, adjuvant therapy (eg, chemotherapy, radiation therapy, HIFU, hormone therapy, etc., following prostatectomy or radiation therapy) may be recommended for aggressive disease.
[0213] Methods for detecting somatic mutations
[0214] refer to Figure 1 , the present disclosure includes methods for detecting somatic mutations by nucleic acid sequencing and assessing the tumor mutation burden of a genome.
[0215] In the method for detecting somatic variants, in step S101, a massively parallel nucleic acid sequencing method can be used to obtain sequence reads from a sample containing cancer cells and non-cancerous cells. The read length of the sequence read can range from about 50 to about 5000 nucleotides. The sequence read can be mapped to a reference genome. Error filtering can be performed on the sequence read in step S103. The base call of the nucleotide can be counted in step S105, and position filtering can be performed in step S107. A somatic variant-SNP sequence read base call count matrix can be assembled in step S109. The count matrix can use a set of heterozygous SNP regions of the reference genome. For each heterozygous SNP position, the count matrix has a first element and a second element, and the first element and the second element only count the read sequence of at least the first variant within a read length located at the heterozygous SNP position; and a third element, the third element only counts the read sequence of at least the second variant located within a read length located at the heterozygous SNP position from cancer cells. In step S111, a somatic mutation significance score (S) of the third element may be calculated for each somatic variant within one read length of the heterozygous SNP position. In step S113, a tumor mutation burden of the sample may be calculated based on the somatic mutation significance score.
[0216] A set of heterozygous SNP regions can be identified based on a group of individuals unrelated to the patient.
[0217] In certain embodiments, the position can be thoroughly filtered to remove the polymorphic position. Positions with variants in more than one sample can be considered polymorphic. The presence of related individuals may replicate the variation and create erroneous polymorphic positions. Therefore, before identifying a polymorphism, a group of non-related individuals can be used.
[0218] The SNP position group can be predetermined.If the position is non-repetitive, non-polymorphic and not inclined to high error rate, then these positions may be qualified.This can be estimated from the statistics based on about 100 or more non-related individuals or about 50 or more non-related individuals or about 20 or more non-related individuals or about 10 or more non-related individuals analyzed previously for example.
[0219] In certain embodiments, the number of qualified positions used to calculate the TMB may be 1000 or more or 5000 or more or 100,000 or more or 300,000 or more or 500,000 or more or 1,000,000 or more or 1,500,000 or more or 1,700,000 or more or 1,900,000 or more or 2,000,000 or more.
[0220] In some embodiments, the number of qualified positions used to calculate the TMB can be at least 1000 or at least 5000 or at least 100,000 or at least 300,000 or at least 500,000 or at least 1,000,000 or at least 1,500,000 or at least 1,700,000 or at least 1,900,000 or at least 2,000,000.
[0221] In some embodiments, the number of qualified positions used to calculate the TMB can be 1000 to 3,000,000 or 5000 to 2,500,000, 100,000 to 2,500,000 or 500,000 to 2,500,000.
[0222] In some embodiments, the average read depth may be at least 50x or 100x for the covered portion of the reference genome.
[0223] The sample may contain cancer cells and non-cancer cells. The presence of cancer cells and non-cancer cells in the sample may allow the methods of the invention to detect somatic mutations and distinguish somatic mutations from germline mutations without the use of a comparator sample, such as a germline comparator sample.
[0224] Typically, cancer cells may be present because the sample may be taken from a subject with cancer, and the sample may contain tissue or cells taken from the cancer site. In some embodiments, the sample may be tissue or cells removed from a tumor. In certain embodiments, the sample may be tissue or cells removed from a malignant tumor. In further embodiments, the sample may be tissue or cells removed from a tumor that contains a margin of non-tumor tissue or cells.
[0225] Embodiments of the present invention comprise unique algorithms for use in methods for directly detecting somatic mutations and assessing tumor mutation burden using only a single sample from a subject, without the need for a step for subtracting germline amounts obtained from a comparator sample.
[0226] Figure 2 A graphical representation of germline alleles and germline variants is shown. Figure 2 , the top shows the nucleic acid sequence of a heterozygous variant position with alleles V and W in a germline cell, which is located near a heterozygous SNP with alleles B and A. Each SNP allele is associated with only one variant allele, BV and AW. When detecting these allele pairs, only two unique sequence detections, BV and AW, are expected. In sequencing by fragmentation, only two unique sequence reads, BV and AW, are expected for read lengths covering both the SNP and VAR positions.
[0227] exist Figure 2Note at the top that the probability of having two variant alleles, V and W, associated with B is extremely small to zero.
[0228] exist Figure 2 , the bottom shows the nucleic acid sequence of a homozygous variant position with alleles W and W in a germline cell, which is located near a heterozygous SNP with alleles B and A. Each SNP allele is associated with the same variant allele, namely BW and AW. When detecting these allele pairs, only two unique sequence detections, BW and AW, are expected. In sequencing by fragmentation, only two unique sequence reads, BW and AW, are expected for read lengths covering both the SNP and VAR positions.
[0229] Figure 3 A schematic representation of somatic alleles and somatic variants is shown.
[0230] exist Figure 3 , the top shows the nucleic acid sequence of a heterozygous variant position with alleles V and W in a sample cell, which is located near a heterozygous SNP with alleles B and A. In cells without somatic mutation variants, each SNP allele will be associated with only one variant allele, such as BV and AW. When detecting these allele pairs, only two unique sequence detections, BV and AW, are expected. In sequencing by fragmentation, for read lengths covering both SNP and VAR positions, only two unique sequence reads, BV and AW, are expected. Therefore, for the two normally expected allele pairs BV and AW, there will be relatively large read counts L1 and L2. In cancer cells with somatic mutation variants, the SNP allele will be associated with a second variant allele, such as BW. Therefore, for the new allele pairing BW, there will be a relatively small read count s. The presence of a non-zero count of s indicates that SNP allele B is found or is associated with two different variant alleles V and W. Therefore, V or W can be regarded as de novo mutations, and more specifically somatic mutations. A non-zero count of s indicates that BW originated from cancer cells through somatic mutations.
[0231] exist Figure 3 , the top shows the Het-Het count matrix of heterozygous variant positions with alleles V and W, which are located near heterozygous SNPs with alleles B and A. In the absence of cancer cells or in the absence of somatic mutations, s is zero, and Figure 3 The top becomes equivalent to Figure 2 top.
[0232] Embodiments of the present invention consider the characterization of the allele ratio as a somatic mutation. The allele ratio can be defined as the ratio of non-wild-type bases and can vary between 0 and 100%.
[0233] Typically, the allele ratio describes the fraction of the variant allele relative to the WT reference allele and can vary between 0 and 100%.
[0234] Typically, if there are no cancer cells containing somatic mutations, an allele ratio of zero may be found. Typically, an allele ratio of 100% would indicate that somatic mutations are present at high levels.
[0235] exist Figure 3 , the bottom shows the nucleic acid sequence of the homozygous variant position with alleles W and W in the sample cell, which is located near the heterozygous SNP with alleles B and A. In cells without somatic mutation variants, each SNP allele will be associated with only one variant allele, such as BW and AW. When detecting these allele pairs, only two unique sequence detections, BW and AW, are expected. In sequencing by fragmentation, for the read length covering both the SNP and VAR positions, only two unique sequence reads, BW and AW, are expected. Therefore, for the two normally expected allele pairs BW and AW, there will be relatively large read counts L1 and L2. In cancer cells with somatic mutation variants, the SNP allele will be associated with a second variant allele, such as BV. Therefore, for the new allele pairing BV, there will be a relatively small read count s. The presence of a non-zero count of s indicates that the SNP allele B is found or is associated with two different variant alleles V and W. Therefore, V or W can be regarded as a de novo mutation, and more specifically a somatic mutation. A non-zero count of s indicates that BV originates from the cancer cell through somatic mutation.
[0236] exist Figure 3 , the bottom shows the Hom-Het count matrix for homozygous variant positions with alleles W and W, which are located near heterozygous SNPs with alleles B and A. In the absence of cancer cells or in the absence of somatic mutations, s is zero, and Figure 3 The bottom becomes equivalent to Figure 2 bottom.
[0237] The presence of a non-zero s indicates that SNP allele B is found or associated with two different variant alleles V and W, and thus the presence of a de novo mutation is identified.
[0238] In some embodiments, for variants located near heterozygous SNPs, the third non-zero read count detectable above the noise level can only be derived from somatic mutations in cancer cells. The third significant read count can be obtained in the presence of non-cancerous cells without subtracting any germline amount obtained from the second germline comparator sample. In fact, the second germline comparator sample is not required in this unique algorithm.
[0239] Tumor mutation burden
[0240] Without wishing to be bound by any particular theory, a method for assessing somatic mutation score and tumor mutation burden (TMB) is described below.
[0241] The TMB value according to the present invention can be calculated using sequencing data obtained from a single sample from a subject using a unique algorithm of the present invention that does not require germline subtraction. Sequencing data can be obtained by a variety of methods known in the art, including microelectrophoresis, hybridization sequencing, single molecule real-time observation, and cycle array sequencing.
[0242] The TMB value can be calculated using fragmented sequencing data, which is obtained from a single sample from a subject using a unique algorithm of the present invention that does not require germline subtraction. Only sequence reads with lengths spanning both variants and SNP positions can be included in the assembly of the count matrix. Typically, reads should cover SNPs and positions to be counted. It is not necessary to use a comparator sample to subtract germline. A group of SNP positions can be used to obtain sequencing data. The allele frequency of the SNP can be compared with the variant to determine whether the variant is germline or somatic.
[0243] A SNP region of about one read length can be used to detect variants near the SNP position. The read length can be sufficient to cover the SNP position and the variant position. A set of SNP regions can provide the sequencing data required to detect somatic variants and quantify the TMB value of a sample.
[0244] As used herein, a variant may be "near" a SNP position when the variant is within about one sequencing read length of the SNP position. The SNP region may be ±1 read length about the SNP position.
[0245] Examples of human SNP position panels known in the art include SNP array 6.0 (Affymetrix).
[0246] For SNP regions containing variant positions, a count matrix can be calculated, where each element C(X1, X2) of the count matrix can be the number of mapped reads with non-SNP calls X1 = (T, C, G, or A) and SNP calls X2 = (T, C, G, or A).
[0247] The quantities X, Y and P, Q are respectively Figure 2 and 3 The instances V,W in correspond to B,A.
[0248] The two largest counts in this matrix, C(X,P) ≥ C(Y,Q), can be attributed to one of four positional allele conditions:
[0249] HomHom: C(Y,Q)≤3 leaves only one significant count, C(X,P), which indicates that both the non-SNP and SNP positions are homozygous;
[0250] HetHom: X≠Y and P=Q, which indicates that the non-SNP position is heterozygous and the SNP position is homozygous;
[0251] HomHet: X=Y and P≠Q, which indicates that the non-SNP position is homozygous and the SNP position is heterozygous; and
[0252] HetHet: X≠Y and P≠Q, which indicates that both the non-SNP position and the SNP position are heterozygous.
[0253] HomHet and HetHet conditions with heterozygous SNP positions can be used to distinguish read counts attributable to somatic mutations from read counts attributable to normal germline allele pairings. For samples from subjects with cancer, somatic mutations can be attributed to the presence of cancer cells. This can be done without separately obtaining germline comparator data from separate samples.
[0254] For the above count matrix, the presence of the third largest count C(Z,P) or C(Z,Q) in the matrix can be attributed to somatic mutations of cancer cells.
[0255] When the counts are significantly higher than the background sequencing error rate, the third maximum count can be used to detect somatic mutations. The average error rate E can be calculated from all other counts except the highest three counts. In certain embodiments, the average error rate E can be calculated from the average of all other counts in the matrix except the highest three counts.
[0256] The Phred-like significance score for somatic mutations (which is a chi-square probability with one degree of freedom) can be calculated using Formula I:
[0257] S=(C(Z,P) 2 / (C(Z,P)+C(X,P))+(C(Z,P)-E) 2 / E) / 2*10
[0258] Formula I
[0259] Where C(Z,P) is the third element count, C(X,P) is the first element count, and E is the error rate calculated for all SNP regions from the average of all but the top three counts in the matrix.
[0260] The value of the error rate E can be calculated as the average over all positions and is typically about 1 or less.
[0261] The TMB level can be calculated as the number of positions with S>30 normalized by the total number of positions in the heterozygous SNP region in M bases {N(HomHet)+N(HetHet)}, as shown in Formula II:
[0262] TMB=N(S>30) / (N(HomHet)+N(HetHet))*1000000
[0263] Formula II
[0264] Without wishing to be bound by any particular theory, a method for determining a value for tumor mutation burden (TMB) based on the above description is set forth below.
[0265] TMB values can be calculated using fragmented sequencing data obtained from a single sample from a subject using a unique algorithm of the present invention that does not require germline subtraction. Germline subtraction using a comparator sample is not necessary. A set of SNP positions can be used.
[0266] The sequencing data from a group of SNP regions can be drawn to illustrate the quantity (y-axis) and allele ratio (x-axis) of variant positions. The area under the curve can be an estimation of the existence of somatic variants. Using this arrangement of sequencing data, by integrating the area under the curve, the value of the total number of variants identified as somatic variants can be obtained. The value of the total number of variants identified as somatic variants can be a measure of TMB. Therefore, the measure of TMB can be obtained as the area under the curve from about 15% allele ratio to about 85% allele ratio or to about 65% allele ratio, wherein the curve plots the relationship between the quantity (y-axis) of variant positions in a group of SNP regions and the allele ratio (x-axis) of variants.
[0267] In some embodiments, a measure of TMB can be obtained as the area under the curve of variant counts (y-axis) allele ratios (x-axis) (from about 15% allele ratio to about 50% allele ratio, or from about 15% allele ratio to about 55% allele ratio, or from about 15% allele ratio to about 60% allele ratio, or from about 15% allele ratio to about 65% allele ratio, or from about 15% allele ratio to about 75% allele ratio, or from about 15% allele ratio to about 85% allele ratio).
[0268] In general, the occurrence of somatic mutations in positions with non-wild-type bases may be rare, so the error of high allele ratio values may be less reliable. Therefore, the area under the curve of variant count (y-axis) allele ratio (x-axis) can preferably be taken from about 15% allele ratio to about 65% allele ratio to reduce the error.
[0269] In some embodiments, a measure of the average error rate E can be obtained as the value of a curve of variant counts (y-axis) versus allele ratios (x-axis) at an allele ratio of about 10-15%.
[0270] system
[0271] In the system of the present invention, the results of the sample analysis can be communicated to doctors, caregivers, genetic counselors, patients and other people in a transmittable form, which can be communicated or transmitted to any of the above parties. This form can be varied and can be tangible or intangible. The results can be embodied in descriptive statements, schematic diagrams, photos, charts, images or any other displayable form. Statements and visual forms can be recorded on tangible media (such as paper), computer readable media (such as floppy disks, compressed disks, etc.), or recorded on intangible media (for example, electronic media in the form of websites on emails or the Internet or intranets). In addition, the results can also be recorded in sound form and transmitted by telephone, fax, wireless mobile phones, Internet phones, etc. through any suitable medium (for example, analog or digital cable lines, fiber optic cables, etc.).
[0272] In the system of the present invention, information and data of test results can be generated anywhere and transmitted to different locations. The present invention further encompasses a method for generating test information of at least one patient sample in a transmittable form.
[0273] The computer-based analysis function can be implemented with any suitable language and / or browser. For example, it can be implemented with C language and preferably with object-oriented high-level programming languages (such as Visual Basic, SmallTalk, C++, etc.). The application program can be written to be suitable for a variety of environments, such as the Microsoft Windows environment comprising Windows 98, Windows 2000, Windows NT, etc. In addition, it is also possible to write applications for MacIntosh, SUN, UNIX, or LINUX environments. In addition, the functional steps can also be implemented using general or platform-independent programming languages. Examples of such multi-platform programming languages include, but are not limited to, hypertext markup language (HTML), JAVA, JavaScript, Flash programming language, common gateway interface / structured query language (CGI / SQL), practical extraction report language (PERL), AppleScript, and other system scripting languages, programming language / structured query language (PL / SQL), etc. It is possible to use browsers supporting Java or JavaScript, such as HotJava, Microsoft, Explorer, or Netscape. When active content web pages are used, they may contain Java™ applets or ActiveX™ controls or other active content technologies.
[0274] The analysis function can also be embodied in a computer program product and used in the above-mentioned system or other computer-based or Internet-based systems. Therefore, another aspect of the present invention relates to a computer program product, which includes a computer-usable medium having a computer-readable program code or instruction embodied thereon, for enabling a processor to perform somatic mutation score and / or TMB analysis. These computer program instructions can be loaded onto a computer or other programmable device to produce a machine, so that the instructions executed on the computer or other programmable device create a device for implementing the above-mentioned functions or steps. These computer program instructions can also be stored in a computer-readable memory or medium that can instruct a computer or other programmable device to operate in a particular manner, so that the instructions stored in the computer-readable memory or medium produce a product containing an instruction device for implementing the analysis. The computer program instructions can also be loaded onto a computer or other programmable device, so that a series of operating steps are performed on a computer or other programmable device to produce a computer-implemented process, so that the instructions executed on the computer or other programmable device provide steps for implementing the above-mentioned functions or steps.
[0275] An embodiment of the present invention may provide a non-transitory machine-readable storage medium having stored therein instructions executed by a processor, the instructions causing the processor to perform the steps of a method for determining and calculating TMB.
[0276] Examples of non-volatile, non-transitory machine-readable storage media include various types of read-only memories (ROMs), hard drives, solid-state memory devices, flash drives, compact disk read-only memories (CD-ROMs), DVDs, optical disks, magnetic disks, or any other storage media that can be used to carry or store program code with computer-executable instructions or data structures, and that can be accessed by a general-purpose or special-purpose computer (such as a processor).
[0277] Embodiments of the present invention may provide a computing system that may have one or more processors, one or more memory devices, a file system, a communication module, an operating system, and / or a user interface, each of which may be communicatively coupled.
[0278] The computing system may have an operating system that may be arranged to utilize various hardware and software resources. The operating system may be arranged to receive and execute instructions for the other components of the system.
[0279] Examples of computing systems include laptop computers, desktop computers, server computers, mobile phones or smartphones, tablet computers, and other portable computing systems.
[0280] Examples of computing systems include processors, special purpose or general purpose computers.
[0281] The processor may be arranged to execute instructions stored on a machine-readable storage medium. The processor may include one or more microprocessors, various controllers, digital signal processors, or application-specific integrated circuits, and may receive and / or transmit data, and execute stored instructions to convert data. In some embodiments, the processor may receive, interpret, and execute instructions from program code or various media. The processor may receive and convert data, and store the data in a memory or file. In some embodiments, the processor may fetch instructions from a memory or file and receive the instructions in a memory.
[0282] The machine-readable storage medium may be non-volatile. The memory or medium may store instructions or data files in a file system and may contain a machine-readable storage medium. The machine-readable storage medium may be non-transitory. The machine-readable storage medium may store therein instructions that can be executed by a processor.
[0283] A communication device may be any device, system, or combination of components capable of transmitting and / or receiving data. Data may be transmitted and / or received via a network or communication line. A communication device may be communicatively linked to other components.
[0284] Examples of communication devices include network cards, modems, antennas, infrared or visible communication components, Bluetooth components, communication chipsets, wide area networks, WiFi components, 802.6 or higher devices, and cellular communication devices. Communication devices can exchange data with other components, devices, or systems through lines, wires, or networks.
[0285] The system of the present disclosure may include one or more processors, one or more non-transitory machine-readable storage media, one or more file systems, one or more memory devices, an operating system, one or more communication modules, and one or more user interfaces, each of which may be communicatively linked.
[0286] Some computational biology methods are described in the following literature: for example, Setubal et al., Introduction To Computational Biology Methods (1997); Salzberg et al., Computational Methods In Molecular Biology (1998); Rashidi and Buehler, Bioinformatics Basics: Application In Biological Science And Medicine (2000); Ouelette and Bzevanis, Bioinformatics: A Practical Guide For Analysis Of Gene And Proteins (2001).
[0287] Anticancer Agents
[0288] Immune checkpoint inhibitor drugs can unleash T cells to kill a subject's cancer cells. These drugs block proteins that enable cancer cells to evade the immune system and improve survival.
[0289] Immune checkpoint inhibitors are therapeutic agents that can prevent or inhibit immune cells and / or immune responses from being turned off or downregulated or suppressed by the very cancer cells that are intended to be killed.
[0290] Typically, immune checkpoint inhibitor drugs are effective in less than 13% of subjects with cancer. Therefore, it is useful to be able to select and identify subjects who will benefit from treatment with such drugs.
[0291] Examples of immune checkpoint inhibitors include PD1 inhibitors, ipilimumab (see, e.g., Gulley and Dahut, Nat. Clin. Practice Oncol. (2007) 4: 136-137), tremelimumab (see, e.g., Ribas et al., Oncologist (2007) 12: 873-883), and the agents listed in Table 1.
[0292] Table 1: Checkpoint inhibitors
[0293]
[0294] Additional Definitions
[0295] The following terms or definitions are provided only to aid in the understanding of the present disclosure.
[0296] Unless specifically defined herein, all terms used herein have the same meaning as would be understood by one skilled in the art from the present disclosure.
[0297] Some methods are given in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, Plainview, New York (1989); and Ausubel et al., Current Protocols in Molecular Biology (Suppl. 47), John Wiley & Sons, New York (1999).
[0298] Unless otherwise expressly defined herein, the terms used herein should not be construed to have a scope less than that understood by one of ordinary skill in the art.
[0299] As used herein, a "single nucleotide polymorphism" (SNP) or "SNP locus" is a locus with alleles that differ at a single base, wherein the rarer allele has a frequency of at least 1% in a population.
[0300] As used herein, an "allele" at a locus is the set of all genetic variants that occur at the locus in a population, with each variant being a single "allele." For example, there are typically only two alleles at a SNP locus.
[0301] As used herein, a "variant" is a difference between a test gene sequence and a reference gene sequence. A variant may differ in a single base, or a variant may differ in more than one base. Variants also include insertions and deletions.
[0302] As used herein, a first variant is "linked" to a second variant if both are located on the same chromosomal (maternal or paternal) DNA strand. "Linked" refers to the state in which two or more variants are linked.
[0303] "Positional allele model" is a model representing the linkage between the allele at the test locus and the allele at the SNP locus. In germline, the positional allele model will generally describe the linkage between the paternal allele at the test locus and the paternal allele at the SNP locus, and the linkage between the maternal allele at the test locus and the maternal allele at the SNP locus. In the case where there is a somatic variant at the test locus (i.e., the third possible allele at the test locus), the positional allele model will additionally describe the linkage between the maternal or paternal allele at the test locus and the SNP locus.
[0304] As used herein, "mutation" is described in detail below, but generally refers to nucleotide changes acquired in somatic tissues compared to the germline of a subject. "Mutational load" is described in detail below, but generally refers to the number or proportion of loci analyzed that contain mutations, wherein "high mutational load" or "HML" generally refers to a number or proportion that exceeds a certain reference value or threshold, or a score derived therefrom.
[0305] As used herein, "next generation sequencing" or "NGS" refers to various high-throughput sequencing processes and technologies that parallelize the sequencing process and generate thousands or millions of sequences at the same time. NGS is usually performed by the following steps: first, a DNA sequencing library is generated by in vitro PCR cloning amplification; second, DNA is sequenced by synthesis so that the DNA sequence is determined by adding nucleotides to the complementary chain rather than by the typical chain termination chemistry of Sanger sequencing; third, the spatially separated amplified DNA templates are sequenced simultaneously in a massively parallel process, usually without the need for a physical separation step. NGS parallelization of sequencing reactions can generate hundreds of megabases to gigabases of nucleotide sequence reads in a single instrument run. Unlike conventional sequencing technologies (such as Sanger sequencing) that usually report the average genotype of a collection of molecular aggregates, NGS technology usually digitally tabulates the sequences of many single DNA fragments (sequence reads discussed in detail below), so that low-frequency variants (e.g., variants present at a frequency of less than about 10%, 5%, or 1% in a heterogeneous population of nucleic acid molecules) can be detected. The term "massively parallel" can also be used to refer to the simultaneous generation of sequence information from many different template molecules by NGS.
[0306] NGS strategies can include several methods, including but not limited to: (i) microelectrophoresis; (ii) hybridization sequencing; (iii) real-time observation of single molecules; and (iv) cycle array sequencing. Cycle array sequencing refers to the technology of obtaining the sequence of dense DNA arrays through iterative cycles of template extension and imaging-based data collection. Commercially available cycle array sequencing technologies include, but are not limited to, 454 sequencing used in 454 genome sequencers (Roche Applied Science; Basel); Solexa technology used in, for example, Illumina Genome Analyzer, Illumina HiSeq, MiSeq and NextSeq (San Diego, California), SOLiD platform (Applied Biosystems; Foster City, California), Polonator (Dover / Harvard), and HeliScope single molecule sequencer technology (Helicos; Cambridge, Massachusetts). Other NGS methods include single molecule real-time sequencing (e.g., Pacific Bio) and ion semiconductor sequencing (e.g., Ion Torrent sequencing). For a more detailed discussion of NGS sequencing technology, see, e.g., Shendure and Ji, Next Generation DNA Sequencing, Nat. Biotech. (2008) 26: 1135-1145.
[0307] As used herein, "patient" or "individual" or "subject" refers to a human. A patient, individual or subject can be male or female. A patient, individual or subject can be a patient, individual or subject who has undergone or is undergoing therapeutic intervention for a disease. A patient, individual or subject can also be a patient, individual or subject who has not been previously diagnosed with a disease.
[0308] As used herein, "sample" or "biological sample" refers to samples such as biopsy or tissue samples, frozen samples, blood and blood fractions or products (e.g., serum, platelets, red blood cells, etc.), tumor samples, saliva, bronchoalveolar lavage fluid, cultured cells (e.g., primary cultures), explants and transformed cells, feces, urine, etc.
[0309] "Biopsy" refers to the process of removing a tissue sample for diagnosis or prognostic assessment, and refers to the tissue sample itself. Various biopsy techniques can be applied to the methods of the present disclosure. The biopsy technique applied will depend on the type of tissue to be assessed (e.g., lung, etc.), the size and type of the tumor, and other factors. Representative biopsy techniques include, but are not limited to, excisional biopsy, incisional biopsy, needle biopsy, surgical biopsy, and bone marrow biopsy. "Excisional biopsy" refers to the removal of the entire tumor mass with a small amount of normal tissue around it. "Incisional biopsy" refers to the removal of a wedge of tissue containing the cross-sectional diameter of the tumor. Diagnosis made by endoscopy or fluoroscopy may require a "core needle biopsy" or "fine needle aspiration biopsy," which typically obtains a cell suspension from the target tissue.
[0310] "Body fluid" includes all fluids obtained from a mammal, whether processed (e.g., serum) or unprocessed, which can include, for example, blood, plasma, urine, lymph, gastric juice, bile, serum, saliva, sweat, and cerebrospinal and cerebral fluid. A biological sample is typically obtained from a subject.
[0311] As used herein, "cancer cell sample" or "tumor sample" means a sample comprising at least one cancer cell or a biomolecule derived therefrom. Examples of cancer include lung cancer (e.g., non-small cell lung cancer (NSCLC)), ovarian cancer, colorectal cancer, breast cancer, endometrial cancer, and prostate cancer. Non-limiting examples of such biomolecules include nucleic acids and proteins. Biomolecules "derived from" a cancer cell sample include molecules located within or extracted from a sample and artificially synthesized copies or versions of such biomolecules. An illustrative, non-limiting example of such artificially synthesized molecules includes a PCR amplification product, in which a nucleic acid from a sample serves as a PCR template. "Nucleic acids" of a cancer cell sample include nucleic acids located in a cancer cell or biomolecules derived from a cancer cell.
[0312] As used herein, "score" means a value or set of values selected to provide a quantitative measure of a variable or characteristic of a subject's condition or the degree of mutation load in a sample, and / or to distinguish, differentiate, or otherwise characterize the mutation load. One or more values comprising a score can be based on, for example, quantitative data of one or more sample components resulting in a measured amount obtained from a subject. In certain embodiments, the score can be derived from a single component, parameter, or assessment, while in other embodiments, the score is derived from multiple components, parameters, and / or assessments. The score can be based on or derived from an explanatory function; for example, an explanatory function derived from a particular prediction model using any of a variety of statistical algorithms. "Change in score" can refer to, for example, an absolute change in score from one time point to the next time point, a percentage change in score, or a change in score per unit time (i.e., a rate of change in score).
[0313] As used herein, a "test locus" is a genomic locus (e.g., a single nucleotide at a specified position within a chromosome) whose sequence or genotype is evaluated according to the present disclosure, where mutations at such locus (e.g., compared to a reference genotype or sequence) are potentially counted in a measurement of mutation load.
[0314] As used herein, the term "treatment" or "therapy" or "therapeutic regimen" includes all clinical management of the subject and is intended to maintain, improve, improve or otherwise change the subject's condition of intervention, whether biological, chemical, physical or a combination thereof. These terms can be used synonymously herein. Treatment includes but is not limited to the use of preventive drugs or therapeutic compounds (including small molecules and biological drugs), exercise regimens, physical therapy, dietary adjustments and / or supplements, obesity surgical interventions, the use of therapeutic compounds (prescription or over-the-counter) and any other treatment effective in preventing the disease characterized by HML, delaying the onset of the disease or improving the disease. "Response to treatment" includes the subject's response to any of the above-mentioned treatments, whether biological, chemical, physical or aforesaid combination. "Therapeutic course" relates to the dosage, duration, degree, etc. of a specific treatment or treatment regimen. The initial treatment regimen used herein is the first line of treatment.
[0315] Additional aspects of the present disclosure
[0316] Aspects of the present disclosure include the following:
[0317] A method for detecting the presence of a somatic variant at a test locus in a sample, the method comprising: detecting a first allele at a single nucleotide polymorphism ("SNP") locus and a second allele at the test locus on a first continuous nucleic acid strand from the sample; detecting a third allele at the SNP locus and a fourth allele at the test locus on a second continuous nucleic acid strand from the sample; and detecting the third allele at the SNP locus and a fifth allele at the test locus on a third continuous nucleic acid strand from the sample, wherein the first allele and the third allele are different alleles, and the fourth allele and the fifth allele are different alleles.
[0318] In some embodiments, the second allele and the fourth allele are identical or different alleles. The nucleic acid can be deoxyribonucleic acid (DNA). One or more alleles can be detected by sequencing. One or more alleles can be detected by hybridization. One or more alleles can be detected by polymerase chain reaction (PCR) amplification. The sample can include cells with somatic variants at the test locus and cells without somatic variants at the test locus. The sample can be a tissue sample. The sample can be a tumor sample.
[0319] A method for detecting somatic variants in a sample, the method comprising: detecting a SNP locus that is heterozygous for an individual; detecting a first test allele linked to a first SNP allele at the SNP locus at a test position within a continuous region around the SNP locus; and detecting a second test allele linked to the first SNP allele at the SNP locus at the test position within the continuous region around the SNP locus, wherein the first test allele and the second test allele are different alleles. In some embodiments, further comprising identifying a third test allele linked to a second SNP allele at the SNP locus at the test position within the continuous region around the SNP locus, wherein the first SNP allele and the second SNP allele are different alleles. The first test allele and the third test allele can be the same allele. The first test allele and the third test allele can be different alleles. One or more alleles can be detected by sequencing, hybridization, or by polymerase chain reaction amplification. The sample may include cells having a somatic variant at the test locus and cells not having a somatic variant at the test locus. The sample may be a tissue sample. The sample may be a tumor sample.
[0320] A method for measuring the frequency of somatic variants in a sample, the method comprising: detecting that the sample is a plurality of SNP loci that are heterozygous; in a continuous region around each SNP locus identified in part a, determining a plurality of test loci to detect a plurality of test alleles linked to each SNP allele of each test locus of the plurality of test loci; and determining a variant frequency, the variant frequency including the number of test loci in which the number of test alleles linked to the SNP allele detected is greater than one, the variant frequency being normalized relative to the total number of the determined test loci. One or more alleles can be detected by sequencing, by hybridization, or by polymerase chain reaction amplification. The sample can include cells having somatic variants at the test loci and cells not having somatic variants at the test loci. The sample can be a tissue sample or a tumor sample.
[0321] A system for detecting somatic mutations, the system comprising a plurality of sensors for measuring a positional allele model number for each position in a region surrounding each of a set of predetermined SNPs.
[0322] A method for treating an individual with an immune checkpoint inhibitor, the method comprising: detecting multiple SNP loci for which the individual is heterozygous; within a continuous region around each SNP locus identified in part a, determining multiple test loci to detect multiple test alleles linked to each SNP allele of each test locus of the multiple test loci; determining a variant frequency, the variant frequency including the number of test loci in which the number of test alleles linked to the SNP allele detected is greater than one, the variant frequency being normalized relative to the total number of the determined test loci; and when the variant frequency exceeds a predetermined threshold, administering a therapeutically effective amount of an immune checkpoint inhibitor to the individual. One or more alleles may be detected by sequencing, by hybridization, or by polymerase chain reaction amplification. The sample may include cells having somatic variants at the test locus and cells not having somatic variants at the test locus. The sample may be a tissue sample or a tumor sample.
[0323] All publications, patents, and references specifically mentioned herein are hereby incorporated by reference in their entirety for all purposes.
[0324] Unless otherwise defined, the meaning of all technical terms and scientific terms used herein is the same as that generally understood by those of ordinary skill in the field to which the present invention relates. Although methods and materials similar to or equivalent to the methods and materials described herein can be used to practice or test the present invention, suitable methods and materials are described below. In addition, the materials, methods and examples herein are only illustrative and are not intended to be limiting.
[0325] Although the foregoing disclosure has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be understood by those skilled in the art that various changes and modifications may be practiced within the scope of the invention and the appended claims.
[0326] Examples
[0327] Example 1: Figure 4 Results of a method for detecting and assessing tumor mutation load by nucleic acid sequencing are shown. For a model including homozygous somatic variants located near a heterozygous SNP (Hom / Het), sequence read stacks were mapped to a reference genome (WT) as shown. A count matrix was assembled showing detection of allele pairings GA (55), AA (32), and AG (23). The appearance of the third largest count AG (23) stems from somatic mutations in cancer cells.
[0328] The allele ratio is calculated as the ratio of the different alleles in the VAR position. In this Hom-Het example, the allele ratio = (23 + 1) / (32 + 55 + 23 + 1) * 100 = 21.6%.
[0329] The SNP is heterozygous, with the allele ratio being (32+23) / {(32+23)+(55+1)}×100=49.5% (A / G55:56).
[0330] like Figure 4 As shown, the error rate E is about 1.0. Therefore, the value of S is about
[0331] S = ((23 x 23 / (23 + 55)) + (23 - E)(23 - E) / E) / 2 x 10 = 2679. The value of E is calculated as the average value over all positions and is generally about 1.0 or less.
[0332] For this example location, Figure 6 The medium sample was 306926, with high TMB.
[0333] Example 2: Figure 5 Shown are results of a method for detecting and assessing tumor mutation burden by nucleic acid sequencing.
[0334] In this particular example, the read length is 100 bp and the total SNP window is 100*2-1=199 bp. For this example position, Figure 6 The medium sample was 306926, with high TMB.
[0335] For a model including heterozygous somatic variants located near heterozygous SNPs (Het / Het), a count matrix showing detection of alleles CG(39), GT(34), and GG(7) was assembled. The occurrence of the third largest count, GG(7), arises from somatic mutations in cancer cells.
[0336] The allele ratio is calculated as the ratio of the different alleles in the VAR position. In this Het-Het example, the allele ratio = 39 / (34+7+39)*100 = 48.8%.
[0337] The SNP is heterozygous as T / G.
[0338] Example 3: Figure 6Sequencing data from colon cancer samples are shown. Each curve represents the number of variant positions (Y axis) by the allele ratio % (X axis). One sample shows a large peak representing a high TMB sample. The high peak on the left at very low allele ratio values (less than 10%) reflects the neglected sequencing errors. To count the TMB score, the TMB count is considered to be the area under the curve for allele ratios in the range of 15% to 65%. From Figure 6 The data are shown in Table 2. The last two columns of Table 2 show the total number of qualified positions and TMB values (absolute and normalized values) per 1 Mb. The TMB of sample 306926 is 417 per Mb, and the TMB of sample 306932 is 32.7 per Mb.
[0339] Table 2: TMB of colon cancer samples (per Mb)
[0340] Sample Label Sample ID Coverage Total number of locations MutPos per Mb CTCAATGA 306926 100.3 1720440 717 416.8 TCCGTCTA 306927 119.9 2019276 40 19.8 AGGCTAAC 306928 110.8 1856679 32 17.2 CCATCCTC 306929 104.7 1830688 36 19.7 AGATGTAC 306930 106.1 1913312 56 29.3 TCTTCACA 306931 96.4 1459685 13 8.9 CCGAAGTA 306932 113.7 1926863 63 32.7 CGCATACA 306933 100.0 1706073 49 28.7 AATGTTGC 306934 128.8 2076785 23 11.1 TGAAGAGA 306935 115.8 1904586 52 27.3 AGATCGCA 306936 97.3 1774434 29 16.3 AAGAGATC 306937 124.3 2087068 44 21.1 CAACCACA 306938 139.7 2174624 44 20.2 TGGAACAA 306939 155.4 2123021 30 14.1 CCTCTATC 306940 133.8 2152846 16 7.4 ACAGATTC 306941 118.9 2049170 55 26.8
[0341] Total Locations = Number of selected locations with a coverage area of 50 or greater
[0342] MutPos = number of variant positions with a score of 30 or higher
[0343] Each Mb = MutPos*1000000 / total number of positions
[0344] Typically, a TMB of 10 mutations per Mb is relatively high and corresponds to a total of more than 32,000 somatic mutations when extrapolated to the whole genome.
[0345] refer to Figure 6 , TMB was calculated from positions with a mutation score of 30 or greater and an allele ratio in the range of 15–65% and was counted and normalized by the total number of qualifying positions in Mb. Figure 6 , the data curve shows the number of variant positions (Y-axis) with the desired score.
[0346] Example 4: Figure 7 A graph showing data obtained using the SNP-based method of the present invention for detecting and assessing tumor mutation burden in colon and breast cancer samples by nucleic acid sequencing compared to conventional methods involving subtracting data from germline comparator samples or germline filtering. Figure 7 The data are summarized in Table 3.
[0347] The samples for colon cancer are Colon Micro-Satellite. The samples for breast cancer are a set of 44 patient samples, which are platinum-sensitive breast tumors.
[0348] Table 3: Comparison of TMB analysis of the present invention with conventional methods
[0349]
[0350]
[0351]
[0352] Using the direct SNP-based method of the present invention with only a tumor sample and no second germline comparator sample ( Figure 7 , solid circles), obtained an assessment of tumor mutation burden that was surprisingly superior to conventional methods. Compared with conventional methods, the SNP-based method of the present invention ( Figure 7 , solid circles) surprisingly increases in sensitivity.
[0353] exist Figure 7 In the figure, the hollow and solid circles at the same x-axis position represent the same results as those of the germline filtering ( Figure 7 , hollow circles), compared with the method of the present invention ( Figure 7 , solid circles) are the measurement results of the same patient sample.
[0354] exist Figure 7 In the figure, the X-axis represents the TMB value estimated by whole exome sequencing, where the germline variants are subtracted from the blood-based germline reference sample of each patient. Figure 7 , solid circles) and lineage filtering methods ( Figure 7 , open circles), the same samples were used for whole exome sequencing. This approach is considered the routine “gold standard” and blood-based subtraction removes germline variants.
[0355] exist Figure 7 In the figure, the Y axis shows the method of the present invention ( Figure 7 , solid circles) and lineage filtering methods ( Figure 7 , open circles) compared to the conventional "gold standard" method. Y-axis values were determined from data obtained using the HRD assay.
[0356] More specifically, the SNP-based method of the present invention ( Figure 7 , solid circles) are surprisingly better than for using a database of known germline variants and filtering common variants to try to remove germline background ( Figure 7 , open circles) to assess tumor mutation burden using nucleic acid sequencing. A database of known germline variants was used to sequence the nucleic acids and filter common variants to try to remove germline background ( Figure 7 , open circles) to detect and assess tumor mutation burden, this conventional method provides inaccurate tumor mutation burden levels. Therefore, the unique and direct SNP-based method of the present invention ( Figure 7 , solid circles) compared with the accuracy and sensitivity of the method that attempts to subtract the germline content ( Figure 7 , open circles) surprisingly increased and unexpectedly advantageous.
[0357] Further, the direct SNP-based methods of the present invention surprisingly outperform conventional whole exome sequencing with germline subtraction over a wide range of mutation frequencies from 0.1 mutations per Mb up to 100 mutations per Mb (a 1000-fold increase) because the direct SNP-based methods of the present invention do not require germline subtracted samples and have improved sensitivity. More specifically, the SNP-based methods of the present invention ( Figure 7 , solid circles) do not utilize and do not require paired tumor and germline comparator samples to subtract germline quantities. The SNP-based method of the present invention ( Figure 7 , solid circles) using only tumor samples. The SNP-based methods of the present invention surprisingly detect, identify and isolate somatic mutations from germline samples using only tumor samples.
[0358] More specifically, Figure 7 It is shown that the SNP-based method of the present invention ( Figure 7 , solid circles) than germline filtering ( Figure 7 , open circles) provide more consistent results for whole exome sequencing (indicated as the x-axis). Figure 7 As shown, at about 10 TMB per megabase or about 20 TMB per megabase, the germline filtering method ( Figure 7 , open circles) are inaccurate (deviate from the line). Therefore, germline filtering cannot accurately estimate TMB values below about 10 per megabase, or even below about 20 per megabase.
[0359] Example 5: The method of the present invention uses a unique algorithm for directly detecting somatic mutations and assessing tumor mutation load using only the first single sample from a subject with cancer without a step for subtracting germline amounts, and the method is compared with a method of whole exome sequencing (WES) using paired tumor and germline comparator samples minus germline amounts. The method of the present invention is further compared with the MYCHOICE HRD-PLUS method minus germline comparators.
[0360] Matched tumor and normal DNA from 44 breast and 12 colon tumors were subjected to each of the WES and MYCHOICE HRD-PLUS methods. The MYCHOICE HRD-PLUS assay combines homologous recombination deficiency analysis with resequencing and MSI analysis of 108 genes.
[0361] For one comparison, TMB measures were calculated from WES by identifying all variants in paired samples and subtracting germline variants.
[0362] For different comparisons, MYCHOICE HRD-PLUS was used. This assay targets about 27,000 SNPs distributed across the genome. Sequence reads of about 100 bp were mapped to the set of SNP segments with a window of ±400 bases around each SNP and a maximum of 7 mismatches.
[0363] Several error filters are applied to the mapped sequences to reduce potential ambiguity in mutation calls:
[0364] Reads with multiple mapping locations were ignored;
[0365] The ends of the reads may be prone to sequencing errors, so bases 1-10 and >86 in each read were ignored;
[0366] If both forward (F) and reverse (R) reads of the same insert are mapped, the mapping positions of the forward and reverse reads must correspond to an insert size of 50-500 bp;
[0367] F or R reads must overlap the SNP position;
[0368] If F and R reads overlap, the calls for the reads are combined, and in this case, the SNP calls must be identical;
[0369] Positions in the overlap with different base calls (identifiable sequencing errors) were ignored.
[0370] TMB values were calculated using MYCHOICE HRD-PLUS data in two ways. First, there was a subtraction of germline numbers. In this method, 400 bp of sequence adjacent to each SNP was observed. Variants were identified within these sequence regions, and then germline subtraction was performed using paired samples.
[0371] In a second experiment, TMB values were calculated for the MYCHOICE HRD-PLUS data using only the first single sample from a subject with cancer and the unique algorithm of the present invention that did not require germline subtraction.
[0372] In the second experiment, only sequence reads spanning both variants and SNPs were included in the assembly of the count matrix. The allele frequencies of the SNPs were compared to the variants to determine whether the variants were germline or somatic. Germline subtraction was not used.
[0373] In this second experiment, for all remaining positions, a count matrix was calculated where each element C(X1,X2) is the number of mapped reads with non-SNP call X1 = (T, C, G, or A) and SNP call X2 = (T, C, G, or A). The two largest counts in this matrix, C(X,P) ≥ C(Y,Q), are attributed to one of the four positional allele conditions:
[0374] HomHom: C(Y,Q)≤3 leaves only one significant count, C(X,P), which means that both the non-SNP and SNP positions are homozygous;
[0375] HetHom: X≠Y and P=Q, i.e., the non-SNP position is heterozygous and the SNP position is homozygous;
[0376] HomHet: X = Y and P ≠ Q, i.e., the non-SNP position is homozygous and the SNP position is heterozygous;
[0377] HetHet: X≠Y and P≠Q, ie, both non-SNP and SNP positions are heterozygous.
[0378] HomHet and HetHet conditions with heterozygous SNP positions are used to distinguish reads from cancer and non-cancer cells. For these conditions, the third largest count C(Z,P) or C(Z,Q) of the matrix can be attributed to somatic mutations of cancer cells.
[0379] When the counts are significantly higher than the background sequencing error rate, the third largest count can be used to detect somatic mutations. The average error rate E is calculated from all counts except the highest three counts.
[0380] The Phred-like significance score for somatic mutations (which is the chi-square probability with one degree of freedom) is calculated using Formula I:
[0381] S=(C(Z,P) 2 / (C(Z,P)+C(X,P))+(C(Z,P)-E) 2 / E) / 2*10
[0382] Formula I
[0383] The TMB level is the number of positions with S>30, which is normalized by the total number of positions in the heterozygous SNP region in M bases {N(HomHet)+N(HetHet)} as shown in Formula II:
[0384] TMB=N(S>30) / (N(HomHet)+N(HetHet))*1000000
[0385] Formula II
[0386] The median sequence length used to calculate TMB was 9.7 Mb for WES, 4.6 Mb for MYCHOICEHRD-PLUS with germline subtraction, and 1.9 Mb for the unique algorithm of the present invention that does not require germline subtraction.
[0387] The results of three different methods for determining TMB were compared. The comparison showed that the unique algorithm of the present invention, which does not require germline subtraction, provides surprisingly accurate TMB values. The comparison of TMB results is shown in Table 4.
[0388] Table 4: Comparison of TMB levels obtained with and without germline subtraction
[0389]
[0390] *Correlation coefficient.
[0391] **Mean difference of variants per Mb (with p-value).
[0392] The correlation coefficients in Table 4 show that the method of the present invention using a unique algorithm that does not require germline subtraction provides surprisingly accurate TMB values compared to conventional WES-based methods with germline subtraction and MYCHOICE HRD-PLUS with germline subtraction.
[0393] Thus, the methods of the present invention using a unique algorithm that does not require germline subtraction are unexpectedly advantageous because the methods do not require a germline comparator sample and can be performed on any sample containing cancer and non-cancer cells.
[0394] The method of the present invention, using a unique algorithm that does not require germline subtraction, is a powerful tool because a threshold or reference value for TMB levels can be determined for each disease or population to be evaluated.
Claims
1. A method for detecting somatic variants, the method comprising: include: (a) sequencing cells of a sample; (b) identifying a set of heterozygous SNP positions, wherein each SNP has alleles B and A; (c) detecting variants at a SNP position of two germline allele pairs and positions near the SNP position, wherein the two germline allele pairs are (i) allele B and a first variant allele and (ii) allele A and a second variant allele, wherein the second variant allele may be the same as or different from the first variant allele; as well as (d) detecting a third allele pair, the third allele pair being (iii) allele B and a third variant allele, the third variant allele being different from the first variant allele.
2. The method according to claim 1, wherein each of the allele pairs is detected in a continuous nucleic acid sequence containing one of the SNP positions, such that the variant position is located within a detection length of the SNP position.
3. The method of claim 2, wherein the read length of the continuous nucleic acid sequence is about 100 to 5000 bases.
4. The method according to claim 2, wherein the detection length is 200 to 1000 consecutive base positions on each flank of the SNP position.
5. The method of claim 1, wherein the method does not utilize a separate germline comparator sample. The method of claim 1 , wherein the sample is a cancer tissue sample, a tumor cell sample, or a tumor sample.
7. The method of claim 1, wherein the amount of non-tumor cells in the sample is minimized.
8. The method of claim 1, wherein the tumor sample contains non-tumor cells.
9. The method of claim 1, wherein the allele pairing is detected by massively parallel sequencing, by hybridization, or by amplification.
10. The method of claim 1, wherein the set of heterozygous SNP positions is at least 5000 SNP positions or at least 100,000 SNP positions or at least 500,000 SNP positions or at least 1,000,000 SNP positions or at least 2,000,000 SNP positions.
Citation Information
Patent Citations
Cooling for Inverter-Based Engine-Driven Welding-Type Power Supply
US20190061036A1
